JPMorgan Chase & Co. Forecasts Strong Price Appreciation for Alamar Biosciences (NASDAQ:ALMR) Stock

Alamar Biosciences (NASDAQ:ALMR) had its price objective hoisted by stock analysts at JPMorgan Chase & Co. from $32.00 to $35.00 in a report released on Tuesday,Benzinga reports. The firm currently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s price objective points to a potential upside of 5.42% from the stock’s current price.

Several other research firms have also recently commented on ALMR. Wall Street Zen upgraded Alamar Biosciences to a “hold” rating in a research report on Saturday, April 25th. Zacks Research raised shares of Alamar Biosciences to a “hold” rating in a research note on Wednesday, May 13th. Bank of America assumed coverage on shares of Alamar Biosciences in a report on Tuesday, May 12th. They issued a “neutral” rating and a $27.00 target price on the stock. Stifel Nicolaus set a $32.00 price target on Alamar Biosciences in a report on Tuesday. Finally, Leerink Partners assumed coverage on shares of Alamar Biosciences in a report on Tuesday, May 12th. They issued an “outperform” rating and a $35.00 price objective for the company. Four analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $31.80.

Alamar Biosciences Stock Up 18.6%

NASDAQ ALMR traded up $5.21 during trading on Tuesday, hitting $33.20. 140,909 shares of the company’s stock traded hands, compared to its average volume of 295,728. The stock has a market capitalization of $2.30 billion and a PE ratio of -19.08. Alamar Biosciences has a 12-month low of $18.84 and a 12-month high of $33.49. The business’s 50 day simple moving average is $24.58.

Alamar Biosciences (NASDAQ:ALMR) last issued its earnings results on Tuesday, August 11th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.14. The business had revenue of $29.43 million for the quarter. On average, research analysts expect that Alamar Biosciences will post -1.42 earnings per share for the current fiscal year.

Key Stories Impacting Alamar Biosciences

Here are the key news stories impacting Alamar Biosciences this week:

• Positive Sentiment: Alamar reported second-quarter revenue of $29.43 million, while its adjusted loss of $0.22 per share was better than the analyst consensus loss of $0.36. The earnings beat suggests improving operating execution. Alamar Q2 earnings report
• Positive Sentiment: Management issued 2026 revenue guidance of $116 million to $120 million, above the roughly $113.1 million analyst estimate. The company also outlined plans to place more than 100 instruments and generate over $400,000 in annual pull-through revenue per instrument, indicating confidence in demand for its platform. Alamar 2026 revenue outlook
• Positive Sentiment: Second-quarter revenue reportedly increased 82% year over year, highlighting rapid commercial expansion. Management’s earnings-call commentary also emphasized accelerating instrument adoption and recurring consumables revenue. Alamar Q2 earnings call highlights
• Positive Sentiment: Alamar expanded its global partnership with the Alzheimer’s Disease Data Initiative and Gates Ventures. The collaboration could broaden the use of Alamar’s proteomics technology in Alzheimer’s research and improve the company’s visibility with pharmaceutical and research customers. Alamar global partnership
• Negative Sentiment: Despite the earnings beat and strong growth, Alamar remains unprofitable. The quarterly loss and the absence of a specific profitability target leave investors focused on how quickly revenue growth can translate into improving margins and cash flow.

About Alamar Biosciences

Our mission is to power precision proteomics to enable the earliest detection of disease. We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation.